Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

[1]  Marek Ancukiewicz,et al.  Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[3]  P. Neuhaus,et al.  VEGF‐D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma , 2008, International journal of cancer.

[4]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[5]  G. Demetri,et al.  Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.

[6]  John Smeraglia,et al.  Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.

[7]  Yoshiyuki Suzuki,et al.  Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  Xinping Tan,et al.  Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer , 2007, Molecular Cancer Therapeutics.

[9]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[10]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[11]  J. Desai,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[12]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Zhi-su Liu,et al.  Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[14]  A. Zhu.  Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? , 2006, The oncologist.

[15]  J. Sleeman,et al.  Tumor-induced lymphangiogenesis: a target for cancer therapy? , 2006, Journal of biotechnology.

[16]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[17]  E. Bugianesi,et al.  Steatosis and hepatocellular carcinoma risk. , 2005, European review for medical and pharmacological sciences.

[18]  Wei Wu,et al.  Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. , 2005, Hepatobiliary & pancreatic diseases international : HBPD INT.

[19]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[20]  N. Pryer,et al.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.

[21]  S. Fan,et al.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Fraumeni,et al.  International trends and patterns of primary liver cancer , 2001, International journal of cancer.

[23]  E C Nice,et al.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3 , 2001, The EMBO journal.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[26]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[27]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.